| dc.date.accessioned | 2022-09-20T13:50:02Z | |
| dc.date.available | 2022-09-20T13:50:02Z | |
| dc.date.issued | 2022 | |
| dc.identifier.uri | http://hdl.handle.net/10852/96732 | |
| dc.language.iso | en | en_US |
| dc.relation.haspart | Paper I. Krüger TB, Herlofson BB, Landin MA, Reseland JE. Alendronate alters osteoblast activities. Acta Odontol Scand. 2016;74(7):550-557.doi: 10.1080/00016357.2016.1217041. The article is not available in DUO due to publisher restrictions. The published version is available at: https://doi.org/10.1080/00016357.2016.1217041 | |
| dc.relation.haspart | Paper II. Krüger TB, Herlofson BB, Lian AM, Syversen U, Reseland JE. Targeting a therapeutically relevant concentration of alendronate for studies on osteoblasts in vitro. Acta Odontologica Scandinavica, 2022, doi: 10.1080/00016357.2022.2072522. The article is included in the thesis. Also available at: https://doi.org/10.1080/00016357.2022.2072522 | |
| dc.relation.haspart | Paper III. Krüger TB, Herlofson BB, Lian AM, Syversen U, Reseland JE. Alendronate and omeprazole in combination reduce angiogenic and growth signals from osteoblasts. Bone Rep. 2021;14:100750. doi: 10.1016/j.bonr.2021.100750. The article is included in the thesis. Also available at: https://doi.org/10.1016/j.bonr.2021.100750 | |
| dc.relation.uri | https://doi.org/10.1080/00016357.2016.1217041 | |
| dc.relation.uri | https://doi.org/10.1080/00016357.2022.2072522 | |
| dc.relation.uri | https://doi.org/10.1016/j.bonr.2021.100750 | |
| dc.title | Alendronate alters the activities of osteoblasts and fibroblasts - aggravated by high dosages and combination therapy | en_US |
| dc.type | Doctoral thesis | en_US |
| dc.creator.author | Krüger, Tormod Bjartveit | |
| dc.type.document | Doktoravhandling | en_US |